Tech

High Growth Tech Stocks To Watch In Europe January 2026

As European markets navigate renewed trade and geopolitical uncertainty, with the pan-European STOXX Europe 600 Index ending 0.98% lower, investors are keenly observing high-growth tech stocks that could potentially thrive in this environment. In such a climate, a good stock is often characterized by its ability to adapt to changing market conditions and leverage technological advancements to maintain robust growth trajectories amidst broader economic challenges.

Name

Revenue Growth

Earnings Growth

Growth Rating

Hacksaw

28.53%

33.50%

★★★★★★

Pharma Mar

16.39%

34.00%

★★★★★☆

Bonesupport Holding

25.63%

57.97%

★★★★★★

KebNi

26.69%

73.00%

★★★★★★

CD Projekt

32.94%

48.67%

★★★★★★

Kitron

21.96%

32.95%

★★★★★★

SyntheticMR

18.81%

47.40%

★★★★★☆

Comet Holding

10.94%

38.32%

★★★★★☆

Waystream Holding

17.38%

66.50%

★★★★★☆

Gapwaves

29.76%

59.76%

★★★★★☆

Click here to see the full list of 47 stocks from our European High Growth Tech and AI Stocks screener.

We’ll examine a selection from our screener results.

Simply Wall St Growth Rating: ★★★★★☆

Overview: Pharma Mar, S.A. is a biopharmaceutical company that specializes in the research, development, production, and commercialization of bio-active principles for oncology applications across various international markets with a market cap of €1.36 billion.

Operations: Pharma Mar, S.A. generates its revenue primarily from the oncology segment, amounting to €179.94 million. The company operates across multiple international markets, including Spain, China, and the United States.

Pharma Mar stands out in the European tech landscape, not just for its impressive earnings growth of 5367% over the past year but also due to its robust forecast of 34% annual earnings growth. This performance starkly surpasses the Spanish market’s average, positioning it well above many peers. With R&D investments sharply focused on pioneering biotechnological advancements, Pharma Mar allocates significant resources towards innovation—evident from their presentation at the prestigious J.P. Morgan Healthcare Conference. These strategic moves hint at a promising trajectory, leveraging cutting-edge research to potentially redefine industry standards and maintain a competitive edge in high-growth markets.

BME:PHM Revenue and Expenses Breakdown as at Jan 2026

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Truecaller AB (publ) develops and publishes mobile caller ID applications for individuals and businesses across India, the Middle East, Africa, and internationally, with a market cap of SEK5.18 billion.

Operations: The company generates revenue primarily from its communications software segment, amounting to SEK2.02 billion.

Truecaller’s recent strategic initiatives, including the launch of Family Protection and a partnership with SmartBuy, underscore its commitment to enhancing user engagement and safety in communication. Despite a challenging quarter with revenue falling to SEK 462.4 million from SEK 528.5 million year-over-year, the company’s innovative steps could foster long-term growth in subscription revenues and user stickiness. Truecaller’s R&D focus is evident as it adapts to market needs by offering features that safeguard less tech-savvy users while boosting premium service adoption. This approach not only aligns with evolving consumer expectations but also positions Truecaller favorably within the competitive tech landscape as it plans further expansion into key markets like India by early 2026.

OM:TRUE B Earnings and Revenue Growth as at Jan 2026
OM:TRUE B Earnings and Revenue Growth as at Jan 2026

Simply Wall St Growth Rating: ★★★★★☆

Overview: Comet Holding AG, with a market cap of CHF2.28 billion, offers X-ray and RF power technology solutions across Europe, North America, Asia, and other international markets through its subsidiaries.

Operations: Comet Holding AG generates revenue primarily from its Plasma Control Technologies (CHF287.40 million), X-Ray Systems (CHF109.40 million), and Industrial X-Ray Modules (CHF96.50 million) segments, catering to diverse international markets.

Comet Holding AG’s trajectory in the tech sector is underscored by a robust 10.9% annual revenue growth and an impressive 38.3% forecast in earnings growth, outpacing the broader Swiss market significantly. With R&D expenses climbing to support these advances, Comet has demonstrated a strategic focus on innovation, particularly evident at recent presentations in Davos and Bad Ragaz where they highlighted advancements in electronic components critical for various high-tech applications. This commitment not only fuels their current performance but sets a promising stage for sustained influence within Europe’s tech landscape, despite market volatility noted over the past three months.

SWX:COTN Revenue and Expenses Breakdown as at Jan 2026
SWX:COTN Revenue and Expenses Breakdown as at Jan 2026

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include BME:PHM OM:TRUE B and SWX:COTN.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button